Prospects for viral-based strategies enhancing the anti-tumor effects of ionizing radiation

Seminars in Radiation Oncology

Volumn 11, Issue 4, 2001, Pages 338-345

  Chmura, Steven J ^a,b,c   Gupta, Nalin ^a,b,c   Advani, Sunil J ^a,b,c   Kufe, Donald W ^a,b,c   Weichselbaum, Ralph R ^a,b,c  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; GENE THERAPY; HUMAN; IONIZING RADIATION; PRIORITY JOURNAL; RADIOSENSITIVITY; SOLID TUMOR; VIRUS REPLICATION;

EID: 0034798919     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1053/srao.2001.26019     Document Type: Article

References (95)

1. Spatial and temporal control of gene therapy using ionizing radiation
2. Genetic radiotherapy overcomes tumor resistance to cytotoxic agents
3. Gene therapy targeted by ionizing radiation
4. Strategies for enhancing viral-based gene therapy using ionizing radiation
5. Strategies to adapt adenoviral vectors for targeted delivery
6. Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome
7. p53 prognostication: Paradigm or paradox?
8. p53 tumor suppressor gene therapy for cancer
9. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage
10. DNA damage-induced phosphorylation of p53 at serine 20 correlates with p21 and Mdm-2 induction in vivo
11. Does the p53 up-regulated Gadd45 protein have a role in excision repair?
12. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen
13. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
14. Ionizing radiation-induced cell death
15. Relation of apoptosis to cancer therapy
16. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
17. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents
18. Advances in cancer gene therapy
19. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene
20. Mutant p53 increases radioresistance in rat embryo fibroblasts simultaneously transfected with HPV16-E7 and/or activated H-ras
21. Alterations in oncogene expression and radiosensitivity in the most frequently used SV40-transformed human skin fibroblasts
22. Transformation and radiosensitivity of human diploid skin fibroblasts transfected with SV40 T-antigen mutants defective in RB and p53 binding domains
23. Adenovirus-mediated wild-type p53 gene expression radiosensitizes non-small cell lung cancer cells but not normal lung fibroblasts
24. Prostate cancer radiosensitization in vivo with adenovirus-mediated p53 gene therapy
25. Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection
26. A phase I trial of adenoviral p53 gene therapy for non-small cell lung cancer
27. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer
28. Glutathione therapy: From pro-drugs to genes
29. Gene therapy for colon cancer
30. Gene therapy for ovarian carcinoma
31. Gene therapy for tumors of the central nervous system
32. Cancer chemotherapy using suicide genes
33. Targeting gene therapy to cancer: A review
34. Direct cell killing by suicide genes
35. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors
36. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene
37. Effective treatment of experimental glioblastoma by HSV vector-mediated TNF alpha and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration
38. HSV vector cytotoxicity is inversely correlated with effective TK/GCV suicide gene therapy of rat gliosarcoma
39. Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents
40. Selective enhancement by an antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSV-tk gene
41. Pyrimidine, purine and nitrogen control of cytosine deaminase synthesis in Escherichia coli K 12. Involvement of the glnLG and purR genes in the regulation of codA expression
42. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor
43. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: A negative selection system
44. Six-year results of a multimodality treatment strategy for locally advanced breast cancer
45. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer
46. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group
47. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery
48. Fluorodeoxyuridine-induced radiosensitization and inhibition of DNA double strand break repair in human colon cancer cells
49. Metabolism and mechanism of action of 5-fluorouracil
50. Biochemical pharmacology and analysis of fluoropyrimidines alone and in combination with modulators
51. Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene
52. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo
53. Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts
54. Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity
55. Gap junctions: The "kiss of death" and the "kiss of life"
56. Stimulation of intercellular communication of poor-communicating cells by gap-junction-competent cells enhances the HSV-TK/GCV bystander effect in vitro
57. In situ use of suicide genes for therapy of brain tumours
58. Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1TklSvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors
59. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme
60. The treatment of malignant mesothelioma with a gene modified cancer cell line: A phase I study
61. Gene therapy for malignant mesothelioma: A novel approach for an incurable cancer with increased incidence in Louisiana
62. Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: A phase I trial
63. A phase I/II study of herpes simplex virus type I thymidine kinase "suicide" gene therapy for recurrent glioblastoma
64. A phase I/II dose-escalation study of herpes simplex virus type I thymidine kinase "suicide" gene therapy for metastatic melanoma
65. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
66. DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis
67. Radiation induction of immediate early genes: Effectors of the radiation-stress response
68. Ionizing radiation regulates expression of the c-jun protooncogene
69. Mechanisms of X-ray-mediated protooncogene c-jun expression in radiation-induced human sarcoma cell lines
70. Protein kinase C mediates x-ray inducibility of nuclear signal transducers EGR1 and JUN
71. Ionizing radiation activates transcription of the EGR1 gene via CArG elements
72. Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation
73. Anti-tumor effects of tumor necrosis factor alone or combined with radiotherapy
74. Tumor necrosis factor (TNF)
75. The interaction of 5-fluorouracil, hydroxyurea, and radiation in two human head and neck cancer cell lines
76. Increased injection number enhances adenoviral genetic radiotherapy
77. Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft
78. Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer
79. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
80. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
81. ONYX-015: Clinical data are encouraging
82. p53-dependent cell death/apoptosis is required for a productive adenovirus infection
83. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection
84. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy
85. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
86. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial
87. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer
88. Experimental therapy of human glioma by means of a genetically engineered virus mutant
89. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial
90. Genetically engineered HSV in the treatment of glioma: A review
91. Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus
92. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: A new paradigm for destruction of therapeutically intractable tumors
93. Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus
94. Accumulation of specific RNAs encoding transcriptional factors and stress response proteins against a background of severe depletion of cellular RNAs in cells infected with herpes simplex virus 1
95. Radiation induction of immediate early genes: Effectors of the radiation-stress response